Effortless

When a valuation-sensitive, long-only investor writes a ₹93-crore cheque into a mid-cap stock that has already fallen more than 40% from its peak, the market usually pays attention — even if the move itself looks quiet on the surface.

That’s exactly what happened in early February, when Akash Prakash, through his Singapore-based FII vehicle Amansa Holdings, executed a large bulk purchase in a niche Indian speciality-chemicals company that has spent the better part of the last year in the market’s penalty box.

The transaction involved 11.79 lakh shares bought at ₹791.84 apiece, translating into an investment of roughly ₹93.4 crore in a single shot. The purchase represents about 1.1% of the company’s equity, and when added to Amansa’s pre-existing holding of roughly 1.2–1.3%, takes its stake close to the mid-2% range, subject to routine disclosure variations.

Why the Market Tracks Akash Prakash So Closely

Before naming the company, it’s important to understand why this particular buyer matters.

Akash Prakash is the founder of Amansa Capital, set up in 2006, and is widely regarded as one of the most disciplined India-focused investors in the public markets. His résumé includes senior investment roles at Temasek, GIC, and Morgan Stanley Asset Management, and he has been investing in Indian equities since the early 1990s.

Amansa’s approach is deliberately conservative:

• A concentrated portfolio of roughly 20–25 stocks
• Strong preference for high ROE / ROIC, free-cash-flow-generating businesses
• Clean governance and management quality
• Explicit avoidance of “story stocks” and euphoric valuations
• A 3–5 year investment horizon, with a willingness to sit on cash when markets are expensive

Because of this, Amansa’s bulk deals are rarely interpreted as trading punts. When the fund builds a meaningful position, the market tends to read it as valuation comfort in a fundamentally strong business.

The Company Behind the Trade

The stock in question is Clean Science & Technology Ltd, a speciality-chemicals manufacturer focused on niche, “clean chemistry” processes.

The company supplies performance chemicals and intermediates used across pharma, FMCG, and industrial applications, and has historically enjoyed high operating margins.

From Market Darling to Derated Quality

So why was the stock available at sub-₹800 levels?

During the FY22–FY23 speciality-chemicals boom, Clean Science traded at extremely rich valuations, with the stock touching the ₹1,400–1,600 zone at its peak. As growth normalised, margins cooled from cycle highs, and global chemical demand softened, the market aggressively removed excess valuation.

By late 2025:

• The stock was down over 40% from its highs
• Market capitalisation had shrunk to roughly ₹8,000–8,800 crore
• Growth expectations were reset to more realistic levels

Importantly, the business itself did not structurally break — what broke was the multiple. Adding to this, promoters reduced their stake significantly over the last few years.

Why This Could Be a Turning Point

A fund like Amansa would not deploy nearly ₹100 crore into a mid-cap chemicals name if it believed the company’s moat or governance had materially weakened. As promoter ownership reduces and long-only institutions step in, the shareholder base tends to stabilise. A high-quality FII absorbing over 1% of equity at current prices reduces loose float and raises the quality bar of ownership. For many domestic funds and serious HNIs, “Amansa is buying” acts as a quiet green flag.

Bottom Line

A large, clean bulk purchase by one of India’s most valuation-disciplined investors doesn’t ensure instant upside — but it does meaningfully change the conversation. For a beaten-down quality compounder that has already paid the price for past exuberance, this ₹93-crore signal suggests that at least one serious, long-term investor believes the risk-reward has quietly turned favourable.